Neovasculgen

ApprovedSmall molecule

AArtgen Biotech

Neovasculgen is one of 115 small molecule programs targeting Peripheral Nerve Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Nerve InjuryActive, not recruiting

IschemiaActive, not recruiting

Interstitial CystitisActive, not recruiting

Diabetic FootActive, not recruiting

Peripheral Nerve InjuryPhase 1/Phase 2

Active, not recruiting

IschemiaApproved

Active, not recruiting

Interstitial CystitisPhase 2/Phase 3

Active, not recruiting

Diabetic FootPreclinical

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Diabetic Foot

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Phase 3

1 2

Zyvox

Pfizer

Phase 3

1 3

Cysteine Hydrochloride

Novartis

Phase 3

1 4

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 5

Tygacil

PPrism Pharmaceuticals

Phase 3

1 6

Cubicin

BBaxter Healthcare Corporation

Phase 3

1 7

Neovasculgen

AArtgen Biotech

Approved

1 8

Urokinase

Mmedac GmbH

Phase 3

3 9

Bemiparin

RRovi Pharmaceuticals Laboratories

Phase 3

1 10

Biochaperone Combo

AAdocia

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Clinical Trial

NCT07391319

Q2 2027

Phase 2/3Recruiting

Interstitial Cystitis

NCT07391306

Q4 2027

Phase 2/3Recruiting

Interstitial Cystitis

NCT07459790

Clinical

Trials by Indication[1]

Interstitial Cystitis2 trials

The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions

Recruiting·JJSC NextGen·Phase 2/3·NCT07459790·180 enrolled

The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.

Recruiting·JJSC NextGen·Phase 2/3·NCT07391306·180 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Unknown status·AArtgen Biotech·Phase 1/2·NCT02356809·30 enrolled

Ischemia1 trial

Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia

Completed·AArtgen Biotech·Phase 4·NCT02369809·210 enrolled

Peripheral Nerve Injury1 trial

Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury

Unknown status·AArtgen Biotech·Phase 1/2·NCT02352649·45 enrolled

Diabetic Foot1 trial

Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot

Completed·AArtgen Biotech·N/A·NCT02538705·35 enrolled

2 more indications

Clinical Trial1 trial

The Prospective, Double-blind, Multicenter, Placebo-controlled, Randomized, Comparative Clinical Trial

Recruiting·JJSC NextGen·Phase 3·NCT07391319·144 enrolled

Unspecified1 trial

Efficiency, Safety and Portability of Neovasculgen

Completed·AArtgen Biotech·Phase 2/3·NCT03068585·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Neovasculgen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neovasculgen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neovasculgen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Artgen Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AArtgen Biotech

Neovasculgen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Interstitial Cystitis2 trials

Safety and Efficacy1 trial

Ischemia1 trial

Peripheral Nerve Injury1 trial

Diabetic Foot1 trial

Clinical Trial1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News